Another all-time high revenue for a quarter ending at MNOK 117.5 (MNOK 109.8),
where last year's revenue included an extraordinary MNOK 5.3 grant through the
U.S. Payroll Protection Program related to COVID-19. Revenue for the first half
of 2022 ended at MNOK 233.6 (MNOK 212.4.

Sales growth is driven by the USA with a currency neutral sales increase of 28 %
for the quarter and 29 % for the first half.

Strategic areas of Vascular surgery and Imaging products show high growth with
44 % and 65% for the quarter, and 65% and 50% respectively for the first half.

Currency neutral sales of own products increase 13.4 % for the quarter and 11.2
% for the first half.

Operating profit (EBIT) for the quarter ended at MNOK 37.4 (MNOK 42.7).
Operating profit for the first half ended at MNOK 70.8 (MNOK 71.7). Last year's
EBIT included the above-mentioned grant of MNOK 5.3 for both the quarter and for
the first half.

A dividend of NOK 3.75 per share was paid to the shareholders on the 9th of May
according to the General Meeting resolution on the 27th of April.